A combination of cisplatin-eluting gelatin microspheres and flavopiridol enhances anti-tumour effects in a rabbit VX2 liver tumour model

Author： NITTA N SONODA A SEKO A OHTA S NAGATANI Y TSUCHIYA K OTANI H TANAKA T KANASAKI S TAKAHASHI M MURATA K

Publisher： British Institute of Radiology

ISSN： 0007-1285

Source： British Journal of Radiology, Vol.83, Iss.989, 2010-05, pp. : 428-432

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

The aim of this study was to investigate whether the combination of cisplatin-eluting gelatin microspheres (GMSs) and flavopiridol enhances anti-tumour effects in a rabbit VX2 liver tumour model. Tumour-bearing rabbits (n = 21) were divided into five groups and infused from the proper hepatic artery. Group 1 (n = 5) received cisplatin-eluting GMSs (1 mg kg⁻¹) and flavopiridol (3 mg kg⁻¹), group 2 (n = 5) cisplatin-eluting GMSs alone (1 mg kg⁻¹), Group 3 (n = 5) flavopiridol (3 mg kg⁻¹), Group 4 (n = 3) GMSs alone (1 mg kg⁻¹), and Group 5 (n = 3) was the control group receiving physiological saline (1 ml kg⁻¹). On days 0 and 7 after procedures the liver tumour volume was measured using a horizontal open MRI system and the relative tumour volume growth rates for 7 days after treatment were calculated. On T₁ weighted images, the tumours were visualised as circular, low-intensity areas just below the liver surface. After treatment, the signals remained similar. The relative tumour volume growth rate for 7 days after treatment was 54.2±22.4% in Group 1, 134.1±40.1% in Group 2,166.7±48.1% in Group 3, 341.8±8.6% in Group 4 and 583.1±46.9% in Group 5; the growth rate was significantly lower in Group 1 than the other groups (p<0.05). We concluded that in our rabbit model of liver tumours the combination of cisplatin-eluting GMSs and flavopiridol was effective.